3-(cyclohexylamino)propanesulfonic acid
Star0
Identification
- Generic Name
- 3-(cyclohexylamino)propanesulfonic acid
- DrugBank Accession Number
- DB02219
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 221.317
Monoisotopic: 221.108564169 - Chemical Formula
- C9H19NO3S
- Synonyms
- 3-(Cyclohexylamino)-1-propanesulfonic acid
- 3-Cyclohexylaminopropane-1-sulphonic acid
- CAPS
- External IDs
- WAS-12
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Cyclohexylamines
- Direct Parent
- Cyclohexylamines
- Alternative Parents
- Sulfonyls / Organosulfonic acids / Alkanesulfonic acids / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic homomonocyclic compound / Alkanesulfonic acid / Amine / Cyclohexylamine / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives / Organopnictogen compound / Organosulfonic acid
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4W981O1LXP
- CAS number
- 1135-40-6
- InChI Key
- PJWWRFATQTVXHA-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H19NO3S/c11-14(12,13)8-4-7-10-9-5-2-1-3-6-9/h9-10H,1-8H2,(H,11,12,13)
- IUPAC Name
- 3-(cyclohexylamino)propane-1-sulfonic acid
- SMILES
- OS(=O)(=O)CCCNC1CCCCC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 70815
- PubChem Substance
- 46506121
- ChemSpider
- 63979
- ZINC
- ZINC000002004372
- PDBe Ligand
- CXS
- PDB Entries
- 1n0x / 1rzl / 1y1j / 1y56 / 1z70 / 2a26 / 2a32 / 2bj0 / 2bk9 / 2dd7 … show 90 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Completed Treatment Asthma 1 3 Completed Treatment Clinical Efficacy / Drug Side Effects / Treatment Efficacy 1 3 Completed Treatment ESI-related Bleeding 1 2 Completed Treatment Fatty Liver / Steatohepatitis 1 2, 3 Completed Treatment Multiple Sclerosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.51 mg/mL ALOGPS logP -0.84 ALOGPS logP -0.53 Chemaxon logS -2.2 ALOGPS pKa (Strongest Acidic) -0.53 Chemaxon pKa (Strongest Basic) 10.45 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 66.4 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 55.26 m3·mol-1 Chemaxon Polarizability 24.01 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7722 Blood Brain Barrier + 0.8847 Caco-2 permeable - 0.6466 P-glycoprotein substrate Non-substrate 0.7641 P-glycoprotein inhibitor I Non-inhibitor 0.8597 P-glycoprotein inhibitor II Non-inhibitor 0.9496 Renal organic cation transporter Non-inhibitor 0.8054 CYP450 2C9 substrate Non-substrate 0.8326 CYP450 2D6 substrate Non-substrate 0.8015 CYP450 3A4 substrate Non-substrate 0.6776 CYP450 1A2 substrate Non-inhibitor 0.8639 CYP450 2C9 inhibitor Non-inhibitor 0.8601 CYP450 2D6 inhibitor Non-inhibitor 0.9056 CYP450 2C19 inhibitor Non-inhibitor 0.9027 CYP450 3A4 inhibitor Non-inhibitor 0.9835 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9396 Ames test Non AMES toxic 0.7573 Carcinogenicity Non-carcinogens 0.5293 Biodegradation Not ready biodegradable 0.5239 Rat acute toxicity 1.6309 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.7173 hERG inhibition (predictor II) Non-inhibitor 0.7152
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-001i-9600000000-8d93ffc67e2fe9c40a9e Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-3940000000-996536d4492b4295245f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0090000000-48f9ae02c5f210e0ea6b Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0019-7930000000-fbd55811c4648589aff4 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-05fu-9510000000-d78f1cfe8f0887e72caf Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-06829f5fb7e0295d0dcc Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-053r-9100000000-25dc998aed5a0dfea2d8 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 157.5037541 predictedDarkChem Lite v0.1.0 [M-H]- 147.16689 predictedDeepCCS 1.0 (2019) [M+H]+ 157.8008541 predictedDarkChem Lite v0.1.0 [M+H]+ 149.71379 predictedDeepCCS 1.0 (2019) [M+Na]+ 157.4062541 predictedDarkChem Lite v0.1.0 [M+Na]+ 156.98183 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52